Vimarsana
Biggest News Aggregation in the World

Page 23 - Cellular Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Cellular Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Cellular Therapy Today - Breaking & Trending Today

Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting - Vimarsana News

Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual Meeting

Read trending news, stories and press releases from PMN Wire News about Canadian and international businesses.

Suspension of accreditation will 'not impact' cord blood storage operations: Cordlife - Vimarsana News

Suspension of accreditation will 'not impact' cord blood storage operations: Cordlife

The indefinite suspension of Cordlife's FACT accreditation will remain in place at least until the ongoing investigations by MOH are completed and issues are resolved.

Investigations into Cordlife's mishandling of cord blood likely to take 'another six weeks': Ong Ye Kung - Vimarsana News

Investigations into Cordlife's mishandling of cord blood likely to take 'another six weeks': Ong Ye Kung

Health Minister Ong Ye Kung also advised parents to hold off on requests to transfer cord blood currently stored with Cordlife elsewhere, until the full impact of the breaches is known.

First CRISPR Sickle Cell Patient 'Reborn': FDA Approves Treatment - Vimarsana News

First CRISPR Sickle Cell Patient 'Reborn': FDA Approves Treatment

The FDA's approval of Casgevy, which uses the Nobel Prize-winning gene-editing therapy to treat patients with sicke cell disease, opens the door to many other therapies.

Source: forbes.com
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most - Vimarsana News

New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most

There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver.